ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0303

Extraglandular Manifestations as Initial Presentation in a Cohort of Patients with Primary Sjögren’s Syndrome

Lucia Alascio1, Silvia Papasidero1, María Alejandra Medina1, Juan Manuel Bande1, Silvana Perez1, Eliana Serrano1, Diana Klajn1, Jose Caracciolo1, Rosella Tralice2, Erick Rodríguez2, Felix Romanini2, Anastasia Secco2, Sinda Zalles3, Carolina Segura Escobar3, Julia Demarchi3, Geofredo Guillermo Earsman4, Laura Raiti5, Sofia Velez6 and Alejandro Martinez7, 1Hospital General de Agudos Dr. Enrique Tornú, Buenos Aires, Argentina, 2Hospital Rivadavia, Buenos Aires, Buenos Aires, Argentina, 3Hospital Británico, Buenos Aires, Buenos Aires, Argentina, 4Hospital Británico, Buenos Aires, La Lucila, Argentina, 5Clínica Bessone, Buenos Aires, Buenos Aires, Argentina, 6Consultorio privado de reumatología, Buenos Aires, Argentina, 7Fundación respirar, Buenos Aires, Mexico City, Mexico

Meeting: ACR Convergence 2021

Keywords: Extraglandular manifestation, Sjögren's syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 6, 2021

Title: Sjögren's Syndrome – Basic & Clinical Science Poster (0296–0322)

Session Type: Poster Session A

Session Time: 8:30AM-10:30AM

Background/Purpose: Primary Sjögren’s Syndrome (pSS) is a systemic autoimmune disease which is mostly characterized by the presence of xerophthalmia and xerostomia, caused by the lymphoplasmacytic cell infiltration of the lacrimal and salivary glands. This pathological change can also affect other organs and produce various extraglandular manifestations (EGM), which may precede the typical sicca symptoms. The diversity of clinical presentations may partially explain the delay in diagnosis and determine the prognosis of the disease.

The purpose of this study was to describe the frequency of EGM as initial presentation in a cohort of patients with pSS and to evaluate the delay in diagnosis among patients with EGM versus sicca as initial symptoms. A secondary objective was to correlate disease onset form with age, sex, disease activity, accumulated damage, and other concomitant EGM.

Methods: Multicenter, observational, analytical, cross-sectional study. Consecutive patients ≥ 18 years of age with a diagnosis of pSS were included. Demographic and disease characteristics and clinimetric indices were recorded. EGM were defined by the EULAR-SS disease activity index (ESSDAI). The delay time from the EGM presentation to the diagnosis of the disease, and the time since the pSS diagnosis to the EGM presentation were considered.

Results: One-hundred eleven patients were included, 93% women, mean age 48.7 years (SD 13.2). 97.3% of the patients presented sicca symptoms (being the initial manifestation of the disease in 47% of them) and 90.9% had at least one EGM (being the initial symptom in 53% of the cases). The most frequent initial EGM was joint involvement (70.3%), followed by biological (32.6%) and pulmonary involvement (23.7%). No significant difference was observed in the time from the first manifestation and the diagnosis between the group that started with sicca (92 months [CI95 39.3-134.9] and that with EGM at onset (44.2 months [CI 95 29.2-59.2]); p = 0.063. Patients with EGM as initial symptom were younger at diagnosis compared to those who started with sicca symptoms (46.3 vs 51.4 years, p = 0.042). Mean ESSDAI score was higher in the group with EGM as initial symptom (1.2 vs 0.9; p = 0.002), while mean Sjögren’s Syndrome Disease Activity Index (SSDI) score was higher those with initial sicca symptoms (1.3 vs 0.9; p = 0.023). No significant differences were observed in other disease characteristics, or in the distribution of different EGM between the groups with sicca or EGM onset.

Conclusion: More than half of the patients with pSS presented an extraglandular involvement at disease onset. There were no differences in the time from the first manifestation to the diagnosis between the groups with sicca or extranglandular onset.


Disclosures: L. Alascio, None; S. Papasidero, None; M. Medina, None; J. Bande, None; S. Perez, None; E. Serrano, None; D. Klajn, None; J. Caracciolo, None; R. Tralice, None; E. Rodríguez, None; F. Romanini, None; A. Secco, None; S. Zalles, None; C. Segura Escobar, None; J. Demarchi, None; G. Earsman, None; L. Raiti, None; S. Velez, None; A. Martinez, None.

To cite this abstract in AMA style:

Alascio L, Papasidero S, Medina M, Bande J, Perez S, Serrano E, Klajn D, Caracciolo J, Tralice R, Rodríguez E, Romanini F, Secco A, Zalles S, Segura Escobar C, Demarchi J, Earsman G, Raiti L, Velez S, Martinez A. Extraglandular Manifestations as Initial Presentation in a Cohort of Patients with Primary Sjögren’s Syndrome [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/extraglandular-manifestations-as-initial-presentation-in-a-cohort-of-patients-with-primary-sjogrens-syndrome/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/extraglandular-manifestations-as-initial-presentation-in-a-cohort-of-patients-with-primary-sjogrens-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology